ADAM10 and Dimebolin

Funding year(s): 
2009
Funding to date: 
$150,000

Understanding the hypothesized relationship between ADAM10, a newly identified Alzheimer’s-related gene, and dimebolin, the key ingredient in the anti-Alzheimer’s drug Dimebon.

Researchers

Headshot photo
Sam Gandy, MD, Ph.D.

Sinai Professor of Alzheimer’s Disease Research, Mount Sinai School of Medicine, New York
Associate Director of the Mount Sinai Alzheimer’s Disease Research Center
Chairman, National Medical and Scientific Advisory Council of the Alzheimer’s Association